GlassScriptPhysician profile
Rajive Tandon
NPI 1104878115
$47,003.22
in general payments reported to CMS, 2019-2025
31 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.07 · 2020: $174 · 2021: $2,905 · 2022: $20K · 2023: $21K · 2024: $1,238 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $4,820 · Food and Beverage: $3,616 · Travel and Lodging: $1,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Consulting Fee | $4,820.00 |
| Food and Beverage | $3,616.33 |
| Travel and Lodging | $1,419.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $32,774.27 | 2020-2025 | Tyvaso, Remodulin, Orenitram |
| Verathon INC. | $2,350.00 | 2022-2025 | Bronoscope |
| Abbvie INC. | $2,000.00 | 2023 | |
| Merck Sharp & Dohme LLC | $1,363.60 | 2022-2025 | Winrevair, Recarbrio, Dificid |
| Baxter Healthcare | $1,231.78 | 2022-2023 | Starling System, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Astrazeneca Pharmaceuticals LP | $943.40 | 2020-2024 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $839.70 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.08 | 2020-2024 | Ofev |
| Cardinal Health 200 LLC | $700.00 | 2025 | |
| Harmony Biosciences LLC | $513.12 | 2021-2022 | |
| Grifols USA, LLC | $421.63 | 2021-2024 | Prolastin-C Liquid |
| Electromed, INC. | $402.58 | 2021-2023 | Smartvest |
| Advanced Respiratory, INC | $385.65 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $343.46 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $290.44 | 2020-2024 | Glassia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $232.74 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $229.65 | 2021-2023 | |
| Genzyme Corporation | $173.95 | 2023-2024 | |
| Inari Medical, INC. | $166.37 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $153.78 | 2021-2024 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $121.20 | 2021-2023 | Airduo Digihaler |
| Amgen INC. | $119.71 | 2022-2024 | Tezspire |
| Ani Pharmaceuticals, INC. | $113.84 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $104.33 | 2021-2023 | |
| Mylan Specialty L.P. | $103.39 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $58.45 | 2022-2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $23.99 | 2023 | Acthar |
| Eisai INC. | $19.31 | 2021 | |
| Genentech USA, INC. | $19.16 | 2023 | Xolair |
| Novo Nordisk INC | $17.78 | 2022 | |
| Vapotherm INC | $13.86 | 2023 | Vapotherm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajive Tandon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.